Dong-E-E-Jiao Co. (000423) Q4 2025 earnings summary

Executive summary

• Focuses on R&D, production, and sales of Ejiao and related traditional Chinese medicine products, with a dual strategy of pharmaceuticals and health consumer goods, and cultural and industrial integration.

• Recognized as an industry leader in Ejiao standards and high-quality development in Chinese medicine.

Financial highlights

• Revenue for 2025 reached ¥6.70 billion, up 13.17% year-over-year; net profit attributable to shareholders was ¥1.74 billion, up 11.67% year-over-year.

• Operating cash flow was ¥2.29 billion, up 5.45% year-over-year.

• Basic and diluted EPS were ¥2.70, up 11.57% year-over-year.

• Weighted average ROE increased by 2.06 percentage points to 16.66%.

• Quarterly revenue and net profit showed steady growth, with Q4 being the strongest quarter.

Outlook and guidance

• Announced a cash dividend of ¥14.31 per 10 shares, with no bonus shares or capital increase from reserves.